Novanta's Strategic Acquisition of Riverpoint Medical to Enhance Minimally Invasive Surgery Portfolio

Novanta, a prominent technology company specializing in robotics and photonics, has announced its intention to acquire Riverpoint Medical in a deal valued at $1.45 billion. This strategic move is set to significantly expand Novanta's portfolio within the minimally invasive surgery sector and substantially boost its revenue streams from medical consumables. The acquisition underscores Novanta's commitment to strengthening its position in the medical market and enhancing its long-term financial stability through more predictable income.

The acquisition, which includes an initial payment of $1.2 billion and an additional $250 million milestone payment in early 2027, is anticipated to conclude by the third quarter of 2026. Novanta plans to fund this significant investment through a combination of its existing cash reserves, proceeds from a recent $300 million equity offering, and its current credit facilities. Upon finalization, Riverpoint Medical will be integrated into Novanta's medical solutions business unit, leveraging synergies to drive innovation and market penetration.

Riverpoint Medical, currently a portfolio company under Arlington Capital Partners, is renowned for its development and manufacturing of advanced medical devices. The company's expertise lies in surgical fibers and related technologies, providing critical private-label minimally invasive surgical consumables and instruments to original equipment manufacturers (OEMs). These products are utilized across various medical fields, including sports medicine, trauma care, and cardiovascular surgery, highlighting Riverpoint's strong market presence and specialized capabilities.

Novanta's leadership has articulated that this acquisition is a pivotal step in its overarching strategy to transition towards more sustainable and recurring revenue models. By incorporating Riverpoint's offerings, Novanta aims to mitigate business cyclicality, deepen its collaborative relationships with medical OEMs, and accelerate its overall revenue and cash flow generation. This strategic alignment is expected to yield substantial benefits, reinforcing Novanta's market leadership and innovative prowess.

In 2025, Novanta reported impressive revenue figures, nearing $1 billion. Its automation enabling technologies segment contributed approximately $501 million, while the medical solutions segment generated around $480 million, representing year-over-year growth rates of 2.1% and 4.6%, respectively. This robust financial performance provides a strong foundation for the integration of Riverpoint Medical and the realization of anticipated synergies.

Matthijs Glastra, CEO of Novanta, highlighted the significant growth potential Riverpoint Medical brings to the company. He noted that Riverpoint's revenue and cash flow are currently expanding at double Novanta's rate, with a projected long-term annual revenue growth of 12% to 15%. This acquisition is expected to double Novanta's recurring medical consumables revenue to approximately $300 million, increasing the medical end-market concentration to 60% of total revenue and significantly boosting profit growth.

Arlington Capital Partners, which acquired Riverpoint in 2019, has played a crucial role in its expansion. Under Arlington's stewardship, Riverpoint has successfully diversified its product line, scaled its manufacturing capabilities, and broadened its market reach. Matt Altman, managing partner at Arlington, expressed confidence that Novanta is the ideal new home for Riverpoint, anticipating that the merger will foster greater innovation for customers and create lasting opportunities for the team.

This strategic transaction is poised to solidify Novanta's market position, particularly in the rapidly evolving minimally invasive surgery segment. The integration of Riverpoint Medical's specialized products and technologies is expected to drive significant advancements, offering enhanced solutions to medical professionals and ultimately benefiting patient care. Novanta's calculated investment reflects its forward-thinking approach to expanding its medical solutions division and securing a more resilient financial future.